02-14-2019 11:35 AM CET - Business, Economy, Finances, Banking & Insurance
Print

Melanoma Cancer Diagnostics Market Revenue, Opportunity, Forecast and Value Chain 2018-2028

Press release from: Fact.MR
PR Agency: Fact.MR
Melanoma Cancer Diagnostics
Melanoma Cancer Diagnostics


About the Report

The report on the melanoma cancer diagnostics market provides key insights, forecast, and in-depth analysis on the market. The melanoma cancer diagnostics market report also includes macro-economic and micro-economic factors playing an important role in the growth of the market. Market dynamics such as drivers, trends, opportunity, and challenges are also offered in the study.

The melanoma cancer diagnostics market has also been analyzed on the basis of key regions and countries. Qualitative and quantitative analysis of the melanoma cancer diagnostics market is also included in the research study.

Request Sample Report @ www.factmr.com/connectus/sample?flag=S&rep_id=57

Market Structure

Segment-wise analysis of the melanoma cancer diagnostics is highlighted in the report to identify and provide details on the existing market opportunities. The melanoma cancer diagnostics market is segmented on the basis of test type and end user. These segments are further divided into sub-segments to offer better understanding of melanoma cancer diagnostics market.

Based on the test type, the melanoma cancer diagnostics market is segmented into Fluorescent in Situ Hybridization (FISH) Tests, Immunohistochemical (IHC) Tests, and Comparative Genomic Hybridization (CGH) Tests. On the basis of end-user, the melanoma cancer diagnostics market is segmented into Pathology Laboratories, Hospitals, and Cancer Research Centres.

Request/View Toc@ www.factmr.com/connectus/sample?flag=T&rep_id=57

Key Insights - Melanoma Cancer Diagnostics

Adoption of Artificial Intelligence (AI) for Melanoma Cancer Diagnosis Growing

The adoption of Artificial Intelligence (AI), combined with large image database, is showing promising results in distinguishing malignant from benign moles and other non-cancerous skin conditions.

Researchers in the US, Germany, and France recently conducted a study using artificial intelligence known as deep learning Convolutional Neural Network (CNN). Researchers compared the performance with 58 international dermatologists and found that CNN missed very few melanomas and misdiagnosed benign moles less often than dermatologists. Along with performing image analysis, the network is capable of teaching itself to improve its performance by using a machine learning process.

The process that CNN used in the research is based on an algorithm developed by Google which allows AI to differentiate between thousands of different objects. However, according to some experts, more work and research is necessary to realize the full potential of this technology for skin cancer diagnosis.

Speak To Research Analyst for Detailed Insights @ www.factmr.com/connectus/sample?flag=AE&rep_id=57

Non-Invasive Techniques Show Promising Results in Skin Cancer Diagnostics

Non-invasive skin cancer diagnostics methods are being used on a large scale for skin cancer diagnosis. Although biopsy is considered to be the best way for skin cancer diagnosis, it is leading to a number of complications including infection, scarring, and bleeding. Hence, researchers are focusing on developing less invasive or non-invasive methods for skin cancer diagnosis.

For instance, Pigmented Lesion Assay (PLA) test by DermTech uses sticky adhesive patch to collect skill cells from lesion to diagnose melanoma and clinical trials found that PLA has high sensitivity and very low probability of missing melanoma. Meanwhile, ongoing technological advancements in optical imaging techniques is also resulting in development of new tools in diagnosis and treatment of skin cancer.

Increasing Incidences of Skin Cancer Driving Demand for Melanoma Cancer Diagnostics

According to the World Health Organization (WHO), around 132,000 melanoma skin cancers occur worldwide every year. It is also estimated that about 10% decrease in ozone levels is likely to result in 4,500 melanoma skin cancer cases. There were nearly 300,000 new melanoma of skin cases in 2018, as per the American Institute of Cancer Research.

With the number of skin cancer cases going up in the past few years, focus on providing early detection and diagnosis is increasing. Melanoma cancer is on a rise owing to the changing environmental conditions and increasing exposure to UV rays. This is driving the demand for rapid diagnostics for early detection of melanoma cancer.

Access This Report @ www.factmr.com/checkout/57/S

Governments Initiatives for Early Detection and Skin Cancer Treatment Drive Adoption

With a rise in melanoma related deaths across various countries, melanoma diagnostics and therapeutics is significantly increasing. Government initiatives, along with the advancement in technology is also driving the growth of melanoma cancer diagnostics. Notable initiatives include,

European Skin Care Foundation (ESCF) is strongly focusing on establishing skin cancer centers across Europe. ESCF is also supporting research activities with an emphasis on innovative modalities for diagnosis and treatment.
To effectively manage melanoma in New Zealand and Australia, initiatives have been taken by governments in both the countries for early detection and holistic treatment. The Ministry of Health in New Zealand has established National Cancer Program to provide high quality and timely treatment for cancer.
The Ministry of Health in New Zealand, in partnership with various institutions, is likely to hold cancer control conference in 2019 to discuss major challenges and identify possible solutions.
The Department of Health in Australia review of evidence on effectiveness of public awareness campaigns to increase awareness for need of skin checks among people, with strategies to target high risk groups.
Additional Questions Answered

The report along with the valuable insights on the melanoma cancer diagnostics market provides answers to some of the important questions on melanoma cancer diagnostics market.

Which test type is expected to register the highest growth in the melanoma cancer diagnostics market?
What will be the market share of Cancer research Centers in melanoma cancer diagnostics market?
Which region is likely to remain lucrative in the melanoma cancer diagnostics market?
What factors are driving the growth in the melanoma cancer diagnostics market?
Research Methodology

A robust and unique research methodology is used to offer insights and forecast on the melanoma cancer diagnostics market. In-depth analysis and information provided on the melanoma cancer diagnostics market is based on the primary and secondary research. Interviews with melanoma cancer diagnostics market experts were conducted to identify new growth opportunities and reach qualitative and quantitative conclusions about the growth of the market.

Secondary research was also conducted by using published data and verifying that data with valid sources. Both, primary and secondary research ensure reliability and accuracy of data included in the report.

About FactMR
FactMR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that's why we publish multi-industry global, regional, and country-specific research reports.

Contact Us
FactMR
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Email: sales@factmr.com
Web: www.factmr.com/
Follow Us on Linkedin: www.linkedin.com/company/factmr/

This release was published on openPR.
News-ID: 1588217 • Views: 104
More releasesMore releases

You can edit or delete your press release here: